MitchellS.SteinerMD

PubMed

• 13 citations
  A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Re...
  Mark C Markowski, Ronald Tutrone, Christopher Pieczonka, K Gary Barnette, Robert H Getzenberg, Domingo Rodriguez, Mitchell S Steiner, Daniel R Saltzstein, Mario A Eise...> ;Clinical Cancer Research. 2022 Jul 1
• 4 citations
  The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer.
  Michael A. Maccini, Nicholas Westfall, Adrie van Bokhoven, Marshall Scott Lucia, Wendy Poage, Paul Maroni, Shandra Wilson, Leonard M. Glode, Paul Arangua, Jay Newmark,...> ;The Prostate. 2018 Feb 19
• 14 citations
  Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer
  Evan Y. Yu, Robert H. Getzenberg, Christopher C. Coss, Marc M. Gittelman, Thomas E. Keane, Ronald F. Tutrone, Laurence Belkoff, Robert Given, Joel Bass, Franklin Chu, ...> ;European Urology. 2015 Feb 1
• 46 citations
  Selective Androgen Receptor Modulators (SARMs) Negatively Regulate Triple-Negative Breast Cancer Growth and Epithelial:Mesenchymal Stem Cell Signaling
  Ramesh Narayanan, Sunjoo Ahn, Misty D. Cheney, Muralimohan Yepuru, Duane D. Miller, Mitchell S. Steiner, James T. Dalton> ;Plos One. 2014 Jul 29
• 13 citations
  Selective androgen receptor modulators for the treatment of late onset male hypogonadism
  Christopher C. Coss, Amanda Jones, Michael L. Hancock, Mitchell S. Steiner, James T. Dalton> ;Asian Journal of Andrology. 2014 Mar 1
• 78 citations
  TMPRSS2:ERG Gene Fusion Predicts Subsequent Detection of Prostate Cancer in Patients With High-Grade Prostatic Intraepithelial Neoplasia
  Kyung Park, James T. Dalton, Ramesh Narayanan, Christopher E. Barbieri, Michael L. Hancock, David G. Bostwick, Mitchell S. Steiner, Mark A. Rubin> ;Journal of Clinical Oncology. 2014 Jan 20
• 49 citations
  Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer
  James T. Dalton, Ryan P. Taylor, Michael L. Mohler, Mitchell S. Steiner> ;Current Opinion in Supportive and Palliative Care. 2013 Dec 1
• 89 citations
  Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
  Muralimohan Yepuru, Zhongzhi Wu, Anand Kulkarni, Feng Yin, Christina M. Barrett, Juhyun Kim, Mitchell S. Steiner, Duane D. Miller, James T. Dalton, Ramesh Narayanan> ;Clinical Cancer Research. 2013 Oct 15
• 236 citations
  Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial
  Adrian S. Dobs, Ralph V Boccia, Christopher Charles Croot, Nashat Y Gabrail, James T. Dalton, Michael L. Hancock, Mary Ann Johnston, Mitchell S. Steiner> ;The Lancet. Oncology. 2013 Apr 1
• Conservative management for an entero-adnexal fistula at initial presentation of advanced ovarian carcinoma.
  Shai A, Grikshtas E, Segev Y, Moskovitz M, Bitterman A, Steiner M, Lavie O> ;Curr Oncol. 2013-02-01
• 42 citations
  Prostate Cancer Diagnosis Among Men With Isolated High-Grade Intraepithelial Neoplasia Enrolled Onto a 3-Year Prospective Phase III Clinical Trial of Oral Toremifene
  Samir S. Taneja, Ronald A. Morton, G. Barnette, Paul Sieber, Michael L. Hancock, Mitchell S. Steiner> ;Journal of Clinical Oncology. 2013 Feb 10
• 102 citations
  Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.
  Matthew R Smith, Ronald A Morton, K Gary Barnette, Paul R Sieber, S Bruce Malkowicz, Domingo Rodriguez, Michael L Hancock, Mitchell S Steiner> ;The Journal of Urology. 2013 Jan 1
• 5 citations
  Preclinical Characterization of a Novel Diphenyl Benzamide Selective ERα Agonist for Hormone Therapy in Prostate Cancer
  Christopher C. Coss, Amanda Jones, Deanna N. Parke, Ramesh Narayanan, Christina M. Barrett, Jeffrey D. Kearbey, Karen A. Veverka, Duane D. Miller, Ronald A. Morton, Mi...> ;Endocrinology. 2012 Jan 31
• 9 citations
  Racial Differences in Bone Mineral Density and Fractures in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
  Alicia K. Morgans, Michael L. Hancock, G. Barnette, Mitchell S. Steiner, Ronald A. Morton, Matthew R. Smith> ;The Journal of Urology. 2012 Mar 1
• 25 citations
  Toremifene Decreases Vertebral Fractures in Men Younger Than 80 Years Receiving Androgen Deprivation Therapy for Prostate Cancer
  Matthew R. Smith, S. Bruce Malkowicz, Michael K. Brawer, Michael L. Hancock, Ronald A. Morton, Mitchell S. Steiner> ;The Journal of Urology. 2011 Dec 1
• 249 citations
  The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of...
  James T. Dalton, Kester G. Barnette, Casey E. Bohl, Michael L. Hancock, D. Rodriguez, Shontelle Dodson, Ronald A. Morton, Mitchell S. Steiner> ;Journal of Cachexia, Sarcopenia and Muscle. 2011 Aug 2
• 22 citations
  Factors Associated With Vertebral Fractures in Men Treated With Androgen Deprivation Therapy for Prostate Cancer
  Philip J. Saylor, Ronald A. Morton, Michael L. Hancock, K. Gary Barnette, Mitchell S. Steiner, Matthew R. Smith> ;The Journal of Urology. 2011 Aug 1
• Oncotype Dx in PR-negative tumors in light of the prognostic value of PR expression.
  Shai A, Rivkin A, Leviov M, Steiner M> ;J. Clin. Oncol.. 2011-05-20
• The impact of less than 8% weight loss on overall survival in subjects with non-small cell lung cancer (NSCLC) treated in a phase IIb trial of GTx-024.
  Dodson S, Dobs A, Hancock ML, Johnston MA, Steiner MS> ;J. Clin. Oncol.. 2011-05-20
• Effect of GTx-024, a selective androgen receptor modulator (SARM), on physical function in patients with non-small cell lung cancer (NSCLC) with cancer cachexia.
  Steiner MS, Dobs A, Hancock ML, Johnston MA, Barnette G, Dodson S> ;J. Clin. Oncol.. 2011-05-20
• Factors associated with vertebral fractures in men treated with androgen-deprivation therapy (ADT) for prostate cancer.
  Saylor PJ, Hancock ML, Barnette G, Steiner MS, Morton RA, Smith MR> ;J. Clin. Oncol.. 2011-03-01
• Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer.
  Morgans AK, Hancock ML, Barnette G, Steiner MS, Morton RA, Smith MR> ;J. Clin. Oncol.. 2011-03-01
• 237 citations
  Muscle Wasting in Cancer Cachexia: Clinical Implications, Diagnosis, and Emerging Treatment Strategies
  Shontelle Dodson, Vickie E. Baracos, Aminah Jatoi, William J. Evans, David Cella, James T. Dalton, Mitchell S. Steiner> ;Annual Review of Medicine. 2011 Jan 12
• 9 citations
  Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.
  Matthew R Smith, Ronald A Morton, K Gary Barnette, Paul R Sieber, S Bruce Malkowicz, Domingo Rodriguez, Mitchell S Steiner> ;The Journal of Urology. 2010 Oct 1
• Use of age and BMD to predict fracture risk in men on androgen deprivation therapy.
  Lin D, Smith MR, Morton RA, Steiner MS> ;J. Clin. Oncol.. 2009-05-20
• Join now to see all